Alpha Tau Medical (NASDAQ: $DRTS ( ▼ 0.84% )) has successfully treated its first patient in the United States with its innovative Alpha DaRT therapy for pancreatic cancer—marking a pivotal moment for a company that could transform how we treat solid tumors.

The September 2, 2025 announcement signals the arrival of a potentially game-changing technology in the fight against pancreatic cancer, the third leading cause of cancer-related death in the United States.

Why This Trial Matters

The IMPACT trial (Intratumoral Pancreatic Alpha Combination Trial) targets the 87% of pancreatic cancer patients deemed inoperable at diagnosis—those who face a dismal prognosis with limited benefit from existing therapies. With approximately 66,000 Americans diagnosed annually, the unmet need is staggering.

The multi-center study aims to enroll 30 patients across the U.S., Canada, and Israel, evaluating Alpha DaRT combined with standard mFOLFIRINOX chemotherapy—a fundamentally new approach to treating solid tumors.

The Technology: Precision Warfare Against Tumors

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) delivers devastating alpha particles directly inside tumors through tiny radium-224 impregnated sources, unlike traditional radiation that bombards from outside or chemotherapy that floods the entire system.

Dr. Mark D'Andrea, Principal Investigator at University Cancer Centers in Houston, explains: "The Alpha DaRT sources are designed to emit powerful alpha particles that travel only a short range in tissue. This is ideal for pancreatic tumors, which are surrounded by critical structures."

Alpha particles are extraordinarily lethal to cancer cells but travel only millimeters—creating a destruction zone confined entirely within the tumor while sparing surrounding organs.

Beyond Pancreatic Cancer: A Platform with Vast Potential

The pancreatic cancer trial is merely the tip of the iceberg. Alpha Tau is simultaneously advancing multiple programs:

• Skin Cancer: ReSTART pivotal U.S. trial for recurrent cutaneous squamous cell carcinoma actively enrolling

• Brain Cancer: FDA-approved pilot study for recurrent glioblastoma (GBM), which has "an estimated average survival rate of only 8 months"

• Head & Neck Cancer: Awaiting Japan regulatory approval following successful trial results

• Combination Therapies: Interim results combining Alpha DaRT with pembrolizumab showed 75% response rate versus 19% for pembrolizumab alone

As Dr. Robert Den, Alpha Tau's Chief Medical Officer, recently wrote in Psychology Today: "The landscape of oncology is moving toward multi-pronged, personalized strategies. Combination therapy allows clinicians to design treatments that are biologically rational, patient-specific, and potentially more effective than single-agent approaches."

What Makes Alpha Tau Stand Out

Alpha Tau presents a compelling story for those following the oncology space. With four active FDA-approved IDEs across numerous cancer types, the company isn't betting on a single indication—each successful trial de-risks the platform and expands the addressable market. The company faces multiple near-term catalysts including a Japan regulatory decision expected in H2 2025, completion of the ReSTART trial, and initiation of the U.S. GBM pilot study.

The company recently received strong strategic validation when Oramed Pharmaceuticals invested $36.9 million, calling Alpha DaRT a "truly groundbreaking medical technology" with "exceptional potential," with CEO Nadav Kidron joining Alpha Tau's board. Unlike many clinical-stage companies, Alpha Tau has already achieved MDSAP certification for its Jerusalem facility (meeting U.S., Canada, Japan, Australia, and Brazil standards) and is building a New Hampshire facility - positioning for rapid potential commercialization upon approval.

The targeted radiation therapy market is experiencing explosive growth, with major pharmaceutical companies making billion-dollar acquisitions of similar technologies while still in clinical stages. This context suggests significant potential for companies like Alpha Tau that are advancing innovative approaches in this space.

The Road Ahead

The first U.S. pancreatic cancer patient treatment represents validation that Alpha Tau's technology can be deployed at leading American cancer centers for one of oncology's toughest challenges. This comes at a time when the entire field is shifting toward combination therapies—Dr. Den noted in Psychology Today that monotherapy trials have declined from 70% to 20-30%, reflecting growing confidence that combination regimens outperform single treatments. These approaches can "reduce drug resistance, slow tumor growth, limit cancer spread, halt division of active cancer cells, decrease cancer stem cell populations, and trigger cancer cell death."

This seems to position Alpha DaRT perfectly for the evolving oncology landscape. "This study incorporates a thoughtful design based on our pre-clinical work to explore the integration of Alpha DaRT with chemotherapy," noted Dr. Den, In the article. With its broad pipeline, strong safety profile, encouraging efficacy signals, and multiple near-term catalysts, Alpha Tau appears positioned to emerge as a potential leader in next-generation cancer therapeutics.

"This pilot study is a key part of our broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs," Sofer emphasized. The company is tackling cancers that have resisted conventional treatment for decades. For those following breakthrough oncology technologies, Alpha Tau's unique approach, broad applicability, and approaching milestones make it a company worth watching.

Recent News Highlights from Alpha Tau Medical:

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

<sub>Legal Disclaimers, Terms & Disclosures: 

By using AlphaCatalyst, any related brands thereof, and any affiliated or partner websites operated under the Wall Street Wire Network (collectively referred to as “Services”), you acknowledge that any and all Services provided are for informational and entertainment purposes only and do not constitute a recommendation for any particular stock, company, investment, commodity, security, transaction, or any other method of trading featured anywhere on AlphaCatalyst or affiliated platforms. AlphaCatalyst does not guarantee the accuracy, completeness, or timeliness of the information or Services provided. Views and opinions presented through the Services, whether expressed by contributors, columnists, external partners, or employees, are not specifically endorsed by AlphaCatalyst or the Wall Street Wire Network, and neither entity accepts responsibility or liability for any actions, financial or otherwise, taken directly or indirectly as a result of engaging with any of the Services offered.</sub>

_{AlphaCatalyst, its employees, operator, partners, affiliates, and any other representatives will not, either directly or indirectly, be held liable, accountable, or responsible in any capacity to you or to any third party for any errors, inaccuracies, or omissions from the Services, including but not limited to market quotes, rumors, unverified chatter, financial data, and news reports; for any interruptions, delays, or transmission errors affecting the availability or accuracy of the Services; or for any damages or losses arising from or related to the use of, reliance on, or inability to access the Services. Some content published by AlphaCatalyst may reference market rumors, speculative chatter, or unconfirmed reports. Readers should be aware that while such unofficial information may be associated with market volatility, price movements based on speculative or incomplete data are subject to change rapidly upon further clarification or the release of official news or filings.}

_{AlphaCatalyst reserves the right at any time to modify any part of its Terms of Service or any portion of the Services, including but not limited to the removal or addition of content, features, contributors, or affiliated content providers, or the introduction of any associated fees or usage conditions. Such changes will take effect immediately upon their publication across the Services and will apply to all users from the time of posting. Please note that trading in foreign currencies, stocks, options, and other securities involves substantial risk and may result in significant financial losses. Neither AlphaCatalyst nor its staff recommends that you buy, sell, or hold any security, and no part of the Services constitutes personalized investment advice. All information provided through the Services is general commentary intended for informational and entertainment use only. AlphaCatalyst disclaims any liability for loss or damage, including without limitation any loss of capital, profit, or opportunity, that may arise directly or indirectly from use of or reliance on the information contained within the Services. We encourage all users to conduct their own due diligence and consult with a certified financial advisor or licensed professional before making any financial decisions.}

_{Content produced by or for AlphaCatalyst may not be reproduced, republished in full, or redistributed in any form without prior written permission from AlphaCatalyst or the Wall Street Wire Network, as applicable.}

_{This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from Oramed Pharmaceuticals Inc for promotional media services provided on an ongoing subscription basis to Alpha Tau Medical. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire and full disclaimers this article is subject to are available wallstwire.ai/disclosures and we recommend reading them in full.}

_{We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by the issuer.}